Please ensure Javascript is enabled for purposes of website accessibility

Why NewLink Genetics Shares Fell 10.3% Today

By Todd Campbell - Updated Apr 4, 2017 at 4:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mid-stage trial results fail to impress investors.

What happened

After reporting that a mid-stage clinical trial stumbled, NewLink Genetics Corporation (NLNK) shares lost 10.3% of their value today.

So what

Last year, attention shifted to NewLink's IDO-inhibiting cancer drug pipeline after its once-promising algenpantucel-L failed to achieve its primary endpoint in phase 3 trials.

A person pounds his fist on a table while viewing a declining price chart.

IMAGE SOURCE: GETTY IMAGES.

This morning, investors got a closer look at interim data from a phase 2 trial evaluating its IDO-inhibitor indoximod, and despite arguably competitive response rates, investors were disappointed.

In its trial, indoximod was used alongside Merck & Co. checkpoint inhibitor Keytruda in 60 patients diagnosed with advanced melanoma. The objective response rate to the combination was 52%, and the disease control rate was 73%. For reference, the disease control rate includes patients determined to have a complete response, a partial response, or stable disease. 

These were solid rates, but investors appear worried that they might not match up as competitively to Incyte's competing IDO-inhibitor, epacadostat. In smaller phase 1 trials involving 19 patients, the ORR for epacadostat plus Keytruda was 58%.

Now what:

Indoximod development is continuing as planned, and earlier this year, management reported that its spending on indoximod's R&D will increase substantially as trials expand to include more patients and cancer indications.

Investors should also see initial results for another IDO-inhibitor later this year. The company's GDC-0919 attempts to inhibit IDO in a way that's more similar to Incyte's drug than indoximod, and collaboration partner Roche Holdings is expected to report some phase 1b data in the second half of 2017.

Overall, there's a lot going on at this company, and while the data might not have been as robust as hoped to justify the uptick in development expenses, it seems to me like today's drop was more "sell the news" than anything else.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NewLink Genetics Corporation Stock Quote
NewLink Genetics Corporation
NLNK
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$93.13 (1.23%) $1.13
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.64 (4.07%) $1.63
Incyte Corporation Stock Quote
Incyte Corporation
INCY
$78.19 (4.56%) $3.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.